<?xml version="1.0" ?>
<text author="Hannah Tween, David Peake, David Spooner, Jenny Sherriff" dateCollected="2019-11-03" id="autogum_academic_doc649" shortTile="radiotherapy-palliation" sourceURL="https://www.mdpi.com/2227-9032/7/4/120/htm" speakerCount="0" speakerList="none" title="Radiotherapy for the Palliation of Advanced Sarcomas — The Effectiveness of Radiotherapy in Providing Symptomatic Improvement for Advanced Sarcomas in a Single Centre Cohort" type="academic">
<head>
<s type="frag">
4.	LS	@ord@
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
There	EX	There
is	VBZ	be
little	RB	little
published	VBN	publish
literature	NN	literature
considering	VBG	consider
the	DT	the
role	NN	role
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
in	IN	in
metastatic	JJ	metastatic
sarcoma	NN	sarcoma
,	,	,
although	IN	although
it	PRP	it
is	VBZ	be
recommended	VBN	recommend
as	IN	as
a	DT	a
treatment	NN	treatment
option	NN	option
for	IN	for
palliation	NN	palliation
by	IN	by
both	CC	both
the	DT	the
UK	NNP	UK
bone	NN	bo
and	CC	and
soft	JJ	soft
tissue	NN	tissue
sarcoma	NN	sarcoma
guidelines	NNS	guideline
and	CC	and
the	DT	the
European	NNP	European
Society	NNP	Society
of	IN	of
Medical	NNP	Medical
Oncology	NNP	oncology
(	-LRB-	(
ESMO	NNP	ESMO
)	-RRB-	)
guidelines	NNS	guideline
.	.	.
</s>
<s type="decl">
To	TO	To
the	DT	the
authors	NNS	author
’	POS	's
knowledge	NN	knowledge
this	DT	this
is	VBZ	be
the	DT	the
largest	JJS	large
retrospective	JJ	retrospective
study	NN	study
published	VBN	publish
to	TO	to
date	NN	date
reviewing	VBG	review
the	DT	the
use	NN	use
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
for	IN	for
sarcoma	NN	sarcoma
.	.	.
</s>
<s type="decl">
The	DT	the
results	NNS	result
confirm	VBP	confirm
that	IN	that
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
can	MD	can
successfully	RB	successfully
provide	VB	provide
symptomatic	JJ	symptomatic
benefit	NN	benefit
to	TO	to
patients	NNS	patient
with	IN	with
metastatic	JJ	metastatic
sarcoma	NN	sarcoma
.	.	.
</s>
<s type="decl">
This	DT	this
study	NN	study
is	VBZ	be
limited	VBN	limit
by	IN	by
being	VBG	be
retrospective	JJ	retrospective
such	JJ	such
that	IN	that
the	DT	the
assessment	NN	assessment
of	IN	of
symptomatic	JJ	symptomatic
improvement	NN	improvement
could	MD	could
only	RB	only
be	VB	be
assessed	VBN	assess
from	IN	from
documentation	NN	documentation
in	IN	in
medical	JJ	medical
records	NNS	record
.	.	.
</s>
<s type="decl">
It	PRP	it
was	VBD	be
therefore	RB	therefore
not	RB	not
possible	JJ	possible
to	TO	to
quantify	VB	quantify
the	DT	the
amount	NN	amount
of	IN	of
symptomatic	JJ	symptomatic
improvement	NN	improvement
seen	VBN	see
or	CC	or
indeed	RB	indeed
to	TO	to
be	VB	be
certain	JJ	certain
of	IN	of
the	DT	the
accuracy	NN	accuracy
of	IN	of
the	DT	the
results	NNS	result
.	.	.
</s>
<s type="decl">
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
review	NN	review
,	,	,
however	RB	however
,	,	,
was	VBD	be
to	TO	to
confirm	VB	confirm
that	IN	that
radiotherapy	NN	radiotherapy
does	VBZ	do
have	VB	have
a	DT	a
role	NN	role
in	IN	in
the	DT	the
palliation	NN	palliation
of	IN	of
advanced	VBN	advance
sarcomas	NNS	sarcomas
and	CC	and
to	TO	to
guide	VB	guide
future	JJ	future
prospective	JJ	prospective
studies	NNS	study
to	TO	to
gain	VB	gain
more	RBR	more
accurate	JJ	accurate
evidence	NN	evidence
of	IN	of
the	DT	the
use	NN	use
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
in	IN	in
this	DT	this
setting	NN	set
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
this	DT	this
study	NN	study
was	VBD	be
limited	VBN	limit
by	IN	by
the	DT	the
heterogeneous	JJ	heterogeneous
population	NN	population
studied	VBN	study
.	.	.
</s>
<s type="decl">
Both	DT	both
soft	JJ	soft
tissue	NN	tissue
and	CC	and
bone	NN	bo
sarcomas	NNS	sarcomas
of	IN	of
multiple	JJ	multiple
types	NNS	type
were	VBD	be
included	VBN	include
.	.	.
</s>
<s type="decl">
The	DT	the
radiobiology	NN	radiobiology
of	IN	of
the	DT	the
different	JJ	different
subtypes	NNS	subtype
of	IN	of
sarcoma	NN	sarcoma
has	VBZ	have
not	RB	not
been	VBN	be
well	RB	well
studied	VBN	study
,	,	,
but	CC	but
it	PRP	it
is	VBZ	be
accepted	VBN	accept
that	IN	that
these	DT	these
tumours	NNS	tumours
tend	VBP	tend
to	TO	to
be	VB	be
relatively	RB	relatively
radio-resistant	JJ	radio-resistant
,	,	,
with	IN	with
a	DT	a
high	JJ	high
alpha	NN	alpha
beta	NN	beta
ratio	NN	ratio
.	.	.
</s>
<s type="decl">
There	EX	There
have	VBP	have
been	VBN	be
several	JJ	several
publications	NNS	publication
considering	VBG	consider
the	DT	the
role	NN	role
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
for	IN	for
other	JJ	other
,	,	,
more	RBR	more
common	JJ	common
solid	JJ	solid
tumour	NN	tumour
types	NNS	type
.	.	.
</s>
<s type="decl">
A	DT	a
meta-analysis	NN	meta-analysis
has	VBZ	have
shown	VBN	show
that	IN	that
when	WRB	when
treating	VBG	treat
bone	NN	bo
metastases	NNS	metastase
from	IN	from
a	DT	a
number	NN	number
of	IN	of
different	JJ	different
primary	JJ	primary
tumour	NN	tumour
sites	NNS	site
and	CC	and
histology	NN	histology
’s	POS	's
,	,	,
there	EX	there
appears	VBZ	appear
to	TO	to
be	VB	be
little	JJ	little
short-term	JJ	short-term
symptomatic	JJ	symptomatic
benefit	NN	benefit
in	IN	in
a	DT	a
fractionated	VBN	fractionated
course	NN	course
of	IN	of
radiotherapy	NN	radiotherapy
,	,	,
compared	VBN	compare
to	TO	to
a	DT	a
single	JJ	single
fraction	NN	fraction
.	.	.
</s>
<s type="decl">
Most	JJS	most
oncologists	NNS	oncologist
therefore	RB	therefore
advocate	VBP	advocate
the	DT	the
use	NN	use
of	IN	of
a	DT	a
single	JJ	single
fraction	NN	fraction
to	TO	to
control	VB	control
pain	NN	pain
secondary	JJ	secondary
to	TO	to
bone	NN	bo
metastases	NNS	metastase
.	.	.
</s>
<s type="decl">
With	IN	with
longer	RBR	long
follow-up	NN	follow-up
,	,	,
however	RB	however
,	,	,
it	PRP	it
seems	VBZ	seem
that	IN	that
patients	NNS	patient
treated	VBN	treat
with	IN	with
a	DT	a
fractionated	VBN	fractionated
course	NN	course
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
are	VBP	be
less	RBR	less
likely	JJ	likely
to	TO	to
need	VB	need
retreatment	NN	retreatment
than	IN	than
those	DT	those
given	VBN	give
a	DT	a
single	JJ	single
fraction	NN	fraction
.	.	.
</s>
<s type="decl">
This	DT	this
study	NN	study
demonstrates	VBZ	demonstrate
that	IN	that
selected	VBN	select
patients	NNS	patient
with	IN	with
advanced	JJ	advanced
sarcoma	NN	sarcoma
can	MD	can
benefit	VB	benefit
from	IN	from
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
provided	VBD	provide
their	PRP$	their
prognosis	NN	prognosis
is	VBZ	be
long	RB	long
enough	RB	enough
for	IN	for
the	DT	the
benefits	NNS	benefit
from	IN	from
radiotherapy	NN	radiotherapy
,	,	,
in	IN	in
terms	NNS	term
of	IN	of
symptomatic	JJ	symptomatic
improvement	NN	improvement
,	,	,
to	TO	to
outweigh	VB	outweigh
the	DT	the
inconvenience	NN	inconvenience
of	IN	of
undergoing	VBG	undergo
radiotherapy	NN	radiotherapy
and	CC	and
the	DT	the
associated	VBN	associate
side	NN	side
effects	NNS	effect
that	WDT	that
they	PRP	they
may	MD	may
suffer	VB	suffer
.	.	.
</s>
</p>
<p>
<s type="sub">
As	IN	as
sarcomas	NNS	sarcomas
are	VBP	be
felt	VBN	feel
to	TO	to
be	VB	be
intrinsically	RB	intrinsically
radio-resistant	JJ	radio-resistant
,	,	,
it	PRP	it
can	MD	can
be	VB	be
hypothesized	VBN	hypothesize
that	IN	that
a	DT	a
single	JJ	single
fraction	NN	fraction
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
may	MD	may
not	RB	not
be	VB	be
sufficient	JJ	sufficient
to	TO	to
offer	VB	offer
adequate	JJ	adequate
symptomatic	JJ	symptomatic
benefit	NN	benefit
.	.	.
</s>
<s type="decl">
The	DT	the
results	NNS	result
presented	VBN	present
here	RB	here
suggest	VBP	suggest
a	DT	a
higher	JJR	high
symptomatic	JJ	symptomatic
response	NN	response
rate	NN	rate
with	IN	with
a	DT	a
biological	JJ	biological
effective	JJ	effective
dose	NN	dose
(	-LRB-	(
BED	NN	BED
)	-RRB-	)
of	IN	of
50	CD	@card@
or	CC	or
greater	JJR	great
.	.	.
</s>
<figure>
<s type="frag">
Figure	NN	Figure
3	CD	3
</s>
</figure>
<s type="decl">
b	NN	b
demonstrates	VBZ	demonstrate
an	DT	an
increase	NN	increase
in	IN	in
response	NN	response
rate	NN	rate
with	IN	with
increasing	VBG	increase
BED	NNP	BED
up	RP	up
to	TO	to
50	CD	@card@
Gy4	NNP	Gy4
.	.	.
</s>
<s type="decl">
Beyond	IN	beyond
this	DT	this
point	NN	point
the	DT	the
response	NN	response
is	VBZ	be
maintained	VBN	maintain
but	CC	but
does	VBZ	do
not	RB	not
appear	VB	appear
to	TO	to
increase	VB	increase
further	RBR	far
,	,	,
suggesting	VBG	suggest
very	RB	very
high	JJ	high
doses	NNS	dose
of	IN	of
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
may	MD	may
not	RB	not
be	VB	be
necessary	JJ	necessary
to	TO	to
achieve	VB	achieve
a	DT	a
good	JJ	good
symptomatic	JJ	symptomatic
response	NN	response
in	IN	in
this	DT	this
patient	NN	patient
group	NN	group
.	.	.
</s>
<s type="frag">
The	DT	the
one	CD	one
apparent	JJ	apparent
outlier	NN	outlier
in	IN	in
</s>
<figure>
<s type="frag">
Figure	NN	Figure
3	CD	3
</s>
</figure>
<s type="decl">
b	NN	b
is	VBZ	be
the	DT	the
100	CD	@card@
%	NN	%
symptomatic	JJ	symptomatic
response	NN	response
in	IN	in
patients	NNS	patient
receiving	VBG	receive
a	DT	a
BED	NNP	BED
of	IN	of
30	CD	@card@
–	TO	–
39.9	CD	@card@
,	,	,
this	DT	this
is	VBZ	be
likely	JJ	likely
to	TO	to
be	VB	be
an	DT	an
outlier	NN	outlier
as	IN	as
there	EX	there
was	VBD	be
only	RB	only
one	CD	one
patient	NN	patient
in	IN	in
this	DT	this
group	NN	group
.	.	.
</s>
</p>
<p>
<s type="frag">
Because	IN	because
of	IN	of
the	DT	the
limited	JJ	limited
evidence	NN	evidence
available	JJ	available
in	IN	in
the	DT	the
use	NN	use
of	IN	of
radiotherapy	NN	radiotherapy
for	IN	for
palliation	NN	palliation
in	IN	in
sarcoma	NN	sarcoma
the	DT	the
Royal	NNP	Royal
College	NNP	College
of	IN	of
Radiologists	NNPS	radiologist
</s>
<s type="decl">
Radiotherapy	NN	Radiotherapy
dose	NN	dose
fractionation	NN	fractionation
guidance	NN	guidance
(	-LRB-	(
3rd	JJ	3rd
edition	NN	edition
)	-RRB-	)
recommends	VBZ	recommend
several	JJ	several
different	JJ	different
dose	NN	dose
fractionation	NN	fractionation
schedules	NNS	schedule
(	-LRB-	(
Table	NN	table
5	CD	5
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Excluding	VBG	exclude
8	CD	8
Gy	NN	gy
single	JJ	single
fraction	NN	fraction
and	CC	and
20	CD	@card@
Gy	NNS	gy
in	IN	in
5	CD	5
fractions	NNS	fraction
which	WDT	which
are	VBP	be
commonly	RB	commonly
used	VBN	use
schedules	NNS	schedule
for	IN	for
all	DT	all
solid	JJ	solid
tumours	NNS	tumours
;	:	;
the	DT	the
remaining	VBG	remaining
recommended	VBN	recommend
dose	NN	dose
fractionation	NN	fractionation
schedules	NNS	schedule
all	DT	all
have	VBP	have
a	DT	a
BED	NNP	BED
of	IN	of
greater	JJR	great
than	IN	than
50	CD	@card@
Gy4	NNP	Gy4
.	.	.
</s>
<s type="decl">
Although	IN	although
this	DT	this
case	NN	case
series	NN	series
has	VBZ	have
demonstrated	VBN	demonstrate
that	IN	that
very	RB	very
high	JJ	high
doses	NNS	dose
of	IN	of
radiotherapy	NN	radiotherapy
may	MD	may
not	RB	not
provide	VB	provide
additional	JJ	additional
short-term	JJ	short-term
symptomatic	JJ	symptomatic
benefit	NN	benefit
,	,	,
longer	JJR	long
courses	NNS	course
of	IN	of
radiotherapy	NN	radiotherapy
may	MD	may
be	VB	be
considered	VBN	consider
in	IN	in
patients	NNS	patient
with	IN	with
a	DT	a
good	JJ	good
performance	NN	performance
status	NN	status
and	CC	and
prognosis	NN	prognosis
in	IN	in
an	DT	an
attempt	NN	attempt
to	TO	to
provide	VB	provide
a	DT	a
longer	JJR	long
period	NN	period
of	IN	of
symptomatic	JJ	symptomatic
benefit	NN	benefit
without	IN	without
the	DT	the
need	NN	need
for	IN	for
retreatment	NN	retreatment
.	.	.
</s>
<s type="decl">
A	DT	a
previously	RB	previously
published	VBN	publish
case	NN	case
series	NN	series
of	IN	of
17	CD	@card@
patients	NNS	patient
who	WP	who
received	VBD	receive
palliative	JJ	palliative
radiotherapy	NN	radiotherapy
for	IN	for
sarcoma	NN	sarcoma
using	VBG	use
39	CD	@card@
Gy	NNS	gy
in	IN	in
13	CD	@card@
fractions	NNS	fraction
over	IN	over
two	CD	two
and	CC	and
a	DT	a
half	JJ	half
weeks	NNS	week
demonstrated	VBN	demonstrate
this	DT	this
was	VBD	be
well	RB	well
tolerated	VBN	tolerate
and	CC	and
provided	VBN	provide
high	JJ	high
rates	NNS	rate
of	IN	of
durable	JJ	durable
pain	NN	pain
control	NN	control
.	.	.
</s>
<s type="sub">
Collection	NN	Collection
of	IN	of
survival	NN	survival
data	NNS	datum
may	MD	may
help	VB	help
to	TO	to
assess	VB	assess
if	IN	if
the	DT	the
correct	JJ	correct
patients	NNS	patient
are	VBP	be
being	VBG	be
offered	VBN	offer
higher	JJR	high
dose	NN	dose
,	,	,
longer	JJR	long
courses	NNS	course
of	IN	of
radiotherapy	NN	radiotherapy
.	.	.
</s>
<figure>
<s type="frag">
Figure	NN	Figure
4	CD	4
</s>
</figure>
<s type="imp">
however	RB	however
does	VBZ	do
not	RB	not
appear	VB	appear
to	TO	to
show	VB	show
any	DT	any
correlation	NN	correlation
between	IN	between
the	DT	the
BED	NNP	BED
of	IN	of
the	DT	the
radiotherapy	NN	radiotherapy
delivered	VBN	deliver
and	CC	and
overall	JJ	overall
survival	NN	survival
.	.	.
</s>
<s type="decl">
Interpretation	NN	interpretation
of	IN	of
this	DT	this
data	NN	datum
is	VBZ	be
extremely	RB	extremely
limited	VBN	limit
because	IN	because
of	IN	of
the	DT	the
heterogeneity	NN	heterogeneity
of	IN	of
the	DT	the
patient	JJ	patient
population	NN	population
with	IN	with
multiple	JJ	multiple
different	JJ	different
histological	JJ	histological
subtypes	NNS	subtype
and	CC	and
the	DT	the
small	JJ	small
numbers	NNS	number
of	IN	of
patients	NNS	patient
treated	VBN	treat
with	IN	with
each	DT	each
dose	NN	dose
and	CC	and
fractionation	NN	fractionation
schedule	NN	schedule
.	.	.
</s>
</p>
<p>
<s type="decl">
To	TO	To
gain	VB	gain
a	DT	a
better	JJR	good
understanding	NN	understanding
of	IN	of
the	DT	the
most	RBS	most
appropriate	JJ	appropriate
dose	NN	dose
and	CC	and
fractionation	NN	fractionation
schedules	NNS	schedule
for	IN	for
different	JJ	different
sarcoma	NN	sarcoma
subtypes	NNS	subtype
large	JJ	large
volume	NN	volume
,	,	,
multicentre	NN	multicentre
,	,	,
prospective	JJ	prospective
data	NNS	datum
collections	NNS	collection
is	VBZ	be
required	VBN	require
using	VBG	use
a	DT	a
small	JJ	small
number	NN	number
of	IN	of
different	JJ	different
dose	NN	dose
and	CC	and
fractionation	NN	fractionation
schedules	NNS	schedule
,	,	,
ideally	RB	ideally
those	DT	those
outlined	VBN	outline
by	IN	by
the	DT	the
Royal	NNP	Royal
College	NNP	College
of	IN	of
Radiologists	NNPS	radiologist
(	-LRB-	(
Table	NNP	table
5	CD	5
)	-RRB-	)
.	.	.
</s>
</p>
</text>
